IDH1 and astrocytoma (excluding glioblastoma): 1. Diagnosis and typing: To confirm GBM and distinguish between IDH wild-type glioblastoma, CNS WHO grade 4, and IDH-mutant astrocytoma, CNS WHO grade 4, which is a core indicator in the WHO grading system.2. Prognostic stratification: Provides initial prognostic information for patients, serving as an important basis for clinical decision-making and patient consultation.3. Treatment exploration: Inhibitors targeting IDH mutant enzymes (such as Vorasidenib) are currently in clinical trials and are expected to become targeted treatment strategies.